| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | JQ12 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.02 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.03 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.078 | 0.03 |